Skerlj, Renato T.’s team published research in Journal of Medicinal Chemistry in 2010 | CAS: 2403-66-9

3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol(cas: 2403-66-9) belongs to imidazoles.Imidazole rings are also present in imidazole ring alkaloids, which are potential therapeutics for thrombosis, cancer and inflammatory diseases.Application In Synthesis of 3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol Although other azole heterocycles are ubiquitous in a wide range of biologically active natural products, imidazole rings occur predominantly in the natural amino acid histidine.

《Discovery of Novel Small Molecule Orally Bioavailable C-X-C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication》 was written by Skerlj, Renato T.; Bridger, Gary J.; Kaller, Al; McEachern, Ernest J.; Crawford, Jason B.; Zhou, Yuanxi; Atsma, Bem; Langille, Jonathon; Nan, Susan; Veale, Duane; Wilson, Trevor; Harwig, Curtis; Hatse, Sigrid; Princen, Katrien; De Clercq, Erik; Schols, Dominique. Application In Synthesis of 3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol And the article was included in Journal of Medicinal Chemistry on April 22 ,2010. The article conveys some information:

The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small mol., orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N’-((1H-benzo[d]imidazol-2-yl)methyl)-N’-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, resp., while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small mol. orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection. The experimental process involved the reaction of 3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol(cas: 2403-66-9Application In Synthesis of 3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol)

3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol(cas: 2403-66-9) belongs to imidazoles.Imidazole rings are also present in imidazole ring alkaloids, which are potential therapeutics for thrombosis, cancer and inflammatory diseases.Application In Synthesis of 3-(1H-Benzo[d]imidazol-2-yl)propan-1-ol Although other azole heterocycles are ubiquitous in a wide range of biologically active natural products, imidazole rings occur predominantly in the natural amino acid histidine.

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem